Aumolertinib Effectively Reduces Clinical Symptoms of an EGFR L858R-Mutant Non-Small Cell Lung Cancer Case Coupled With Osimertinib-Induced Cardiotoxicity: Case Report and Review

Aumolertinib Effectively Reduces Clinical Symptoms of an EGFR L858R-Mutant Non-Small Cell Lung Cancer Case Coupled With Osimertinib-Induced Cardiotoxicity: Case Report and Review

Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) first-line therapy, has shown good clinical outcomes in non-small cell lung cancer (NSCLC), but some serious adverse events such as cardiotoxicity have also been reported. Here, we present the first...

Full description

Bibliographic Details
Main Authors: Qianqian Zhang, Haiyang Liu, Jia Yang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Endocrinology
Subjects:
aumolertinib
L858R
osimertinib
cardiac failure
NSCLC
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2022.833929/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2022.833929/full

Similar Items